Open Orphan PLC (AIM:ORPH, OTC:OPORF) (Open Orphan PLC (AIM:ORPH, OTC:OPORF), Open Orphan PLC (AIM:ORPH, OTC:OPORF)) subsidiary hVIVO has inoculated the first group of volunteers as part of its first controlled human malaria infection challenge study.
Adrian Wildfire, Director of Scientific & Business Strategy at hVIVO talks to Proactive London's Katie Pilbeam about how their team will assess the standard of care antimalarial treatments against plasmodium malaria.
Following the completion of the evaluation, hVIVO will then be able to sign human challenge study contracts to assess the efficacy of new antimalarial drugs and vaccines.
There were 241mln malaria cases and 627,000 deaths from the disease in 2020.